Theralase Technologies Inc. V.TLT

Phase 1 IO-PDT of NSCLC with Photofrin has New Start Date

[Eoganacht]

Roswell Park first posted this 12 patient, phase 1 trial on clinicaltrials.gov on Sep. 19, 2018 and no patients have been recruited yet. The new estimated start date is February 28, 2021, and estimated completion date February 28, 2023. The light dosimetry system to be used is Lumeda's DigiLum and the principal investigator is thoracic surgeon, Dr. Saikrishna Yendamuri.

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

There may be another phase 1 trial of this kind planned, but using TLD1433 instead of photofrin, to start in Q2-21. If they decide to use TLD1433, we should hear about it some time in Q1-21.

Lumeda Clinical Studies List

[fredgoodwinson]

Yes EOG they did mention another lung Trial in Q2 with a PS to be decided. TLD-1433 is certainly in the frame and reluctant to be out of the stock atm as if chosen it could be quite soon and the catalyst for a re-rating.

[Rumpl3StiltSkin]

Fred, IF/When this happens for TLT. Then maybe someone from this forum opens a thread, on the wallstreetbets reddit, to let them know about the coming Cancer Cure stock that has been 'held down'. Maybe we also have some good Covid results by then to help this along. :-)

[fredgoodwinson]

Tend to agree Rumpl - have posted previous that given the real potential here maybe an ideal candidate for a lower-risk move by wallstreetbets.

[Hankerchief]

Too bad they are still mucking with photophrin when TLD 1433 can be so much better IMO.

[CancerSlayer]

Hi Hank... Head-to-head, there's no comparison based on potential efficacy & side effect profile.  I'm confident TLD-1433 will take the lead.  With strong results from animal studies, I will sell my shares if they "don't" replace Photofrin & incorporate TLD-1433 into a new trial.  Can't ignore scientific common sense on this one, especially with

[Rumpl3StiltSkin]

Fingers crossed on this, also funding $$ from Cad Govt for U of M Covid study. Could be huge for TLT going forward.

[enriquesuave]

Animal studies were being done with TLD-1433 at Roswell  I guess they are going to decide which PS to use after those studies are completed.  My guess is we should hear very shortly about this.  Imho   

[Eoganacht]

That's right. Sarah Chamberlain talked about work being done at Roswell with rats in her presentation on pre-treatment planning of io-pdt for NSCLC using TLD1433 at the PDT & Photodiagnosis E-CONGRESS in November. I believe you asked her a question about the relative efficacy of photofrin and TLD1433 for this purpose and she replied that results with photofrin were good but TLD1433

[enriquesuave]

Right on Eoganacht.  Animal studies have been underway for a while now so results should be out soon or known I guess. We shall see.

[CancerSlayer]

  Thanks again Eoganacht....just based on the timing of the Roswell Park news & their animal study timeframe, I'm very hopeful there will "soon" be great news of TLD-1433's replacement of Photofrin.  BTW, I noted the estimated duration for this Ph 1 trial would only be 1 yr.  The estimated completion date was reported to be Feb. 28, 2022....guess that's